Lecanemab, a Novel Amyloid β-Directed Antibody for Early Alzheimer Disease

•Lecanemab is the second anti-amyloid monoclonal antibody that has received approval for treatment in patients with Alzheimer disease with mild cognitive impairment or mild dementia stage of Alzheimer disease via expedited pathway by the Food and Drug Administration. •The Clarity AD phase 3 trial showed 27% slowing of dementia decline via Clinical Dementia Rating Sum of Boxes at 18 months with a relatively high incidence of infusing reactions and brain hemorrhage and edema. •The need for frequent adverse effect monitoring, the nature of the adverse effects, and high cost might limit its use in practice Both authors are at Long Island University (LIU) Pharmacy, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Brooklyn, NY. Yuliana Toderika, BS, PharmD, BCACP, is an Associate Professor of Pharmacy Practice and is also an ambulatory care pharmacist at One Brooklyn Health, and can be reached at [email protected]. Jadwiga Najib, BS, MPH, PharmD, is a Professor of Pharmacy Practice and is also a clinical pharmacist at Zucker Hillside Hospital of Northwell Health, Glen Oaks, NY. Department Editor Timothy Nguyen, PharmD, BCPS, CCP, FASCP, who would like to hear your ideas for future columns, can be reached at [email protected].